Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes

Journal of Neuro-Oncology

Volumn 32, Issue 1, 1997, Pages 19-28

  Baldwin, Nevan G ^a   Rice, Charles D ^a   Tuttle, Todd M ^a   Bear, Harry D ^a   Hirsch, Jerry I ^a   Merchant, Randall E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activation; Culture; Glioma; Immunotherapy; Lymphocyte; Signal transduction

Indexed keywords

BRYOSTATIN 1; CD3 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; IONOMYCIN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL SUSPENSION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FLOW CYTOMETRY; GLIOMA; LYMPH NODE CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL COMMUNICATION; FEMALE; GLIOMA; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPH NODES; PHENOTYPE; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0031040621     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005719700570     Document Type: Article

References (24)

1. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180-199, 1992
2. Weiss A, Imboden J, Hardy K, Manager B, Terhorst C, Stobo J: The role of the T3 antigen receptor complex in T-cell activation. Ann Rev Immunol 4: 593-619, 1990
3. Imoden JB, Stobo JD: Transmembrane signaling by the T cell antigen receptor. Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. J Exp Med 161: 446-456, 1985
4. Truneh A, Albert F, Goldstein R, Schmitt-Verhulst AM: Early steps of lymphocyte activation by-passed by calcium ionophores and phorbol esters acting in synergy. Nature 313: 318, 1985
5. Shu S, Chou T, Rosenberg SA: Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 139: 295-304, 1987
6. Itoh K, Platsoucas CD, Balch CM: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168: 1419-1441, 1988
7. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147: 729-737, 1991
8. + murine T cells from tumor-draining lymph nodes with phorbol dibutyrate plus calcium ionophore. J Immunother 12: 32-40, 1992
9. Hoover SK, Frank JL, McCrady CW, McKinnon JG, Bear HD: Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancers. J Surg Oncol 46: 117-124, 1991
10. Kraft AS, Smith JB, Berkow RL: Bryostatin, and activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester induced differentiation of human promyelocytic progenitor cells HL-60. Proc Natl Acad Sci USA 83: 1334-1338, 1986
11. McKinnon JG, Hoover SK, Inge TH, Bear HD: Activation and expansion of cytotoxic lymphocytes from tumor-draining lymph nodes. Cancer Immunol Immunother 32: 38-44, 1990
12. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD: Activation and growth of murine tumor-specific T-cells which have in vivo activity with Bryostatin 1. Cancer Res 52: 548-553, 1992
13. Tuttle TM, Inge TH, Wirt CP, Frank JL, McCrady CM, Bear HD : Bryostatin 1 activates T cells which have anti-tumor activity. J Immunother 12: 75-81, 1992
14. Beckman WC, Powers SK, Brown JT, Gillespie GY, Bigner DD, Camps JL: Differential retention of rhodamine-123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. Cancer 59: 266-270, 1987
15. Rice CD, Merchant RE: Murine recombinant interleukin-1β inhibits the growth and progression of malignant glioma in the rat. J Neuro-Oncol 13: 43-55, 1992
16. Watts RG, Merchant RE: Cerebrovascular effects and tumor kinetics after a single intratumoral injection of human recombinant interleukin-2 alone or in combination with intravenous chemotherapy in a rat model of glioma. Neurosurgery 31: 89-99, 1992
17. Wright JL, Merchant RE: Histopathological effects of intracerebral injections of human recombinant tumor necrosis factor-α in the rat. Acta Neuropathol 85: 93-100, 1992
18. Tuttle TM, Bethke KP, Inge TH, McCrady CW, Pettit GR, Bear HD: Bryostatin 1-activated cells can traffic and mediate tumor regression. J Surg Res 52: 543-548, 1992
19. Tuttle TM, Inge TH, Lind DS, Bear HD: Adoptive transfer of Bryostatin 1-activated T cells provides long-term protection from tumor metastases. Surg Oncol 1: 299-307, 1992
20. Rice CD, Baldwin NG, Bear HD, Merchant RE: Adoptive immunotherapy of intracranial glioma models with tumor-sensitized lymphocytes. Proc Am Assoc Cancer Res 36: 474, 1995
21. Brooks WH, Markesbery WR, Gupta GD, Roszman TL: Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4: 219-224, 1978
22. DiLorenzo N, Palma L, Nicole S: Lymphocytic infiltration in long-survival glioblastoma: Possible host's resistance. Acta Neurochir 39: 27-33, 1977
23. Palma L, DiLorenzo N, Guidetti B: Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fat, and relevance to prognosis in 228 operated cases. J Neurosurg 49: 854-861, 1978
24. Ridley A, Cavenaugh JB: Lymphocytic infiltration in gliomas: Evidence of possible host resistance. Brain 94: 117-124, 1971